Corcept Therapeutics Incorporated · NASDAQ:CORT

Corcept Therapeutics — Technical Presentation (December 2024)

15 slides from Corcept Therapeutics's technical presentation, Dec 12, 2024

  1. Slide 1: Relacorilant Improved Blood Pressure and Maintained Other Cardiometabolic Improvements

    Relacorilant Improved Blood Pressure and Maintained Other Cardiometabolic Improvements in Long-term Study in Patients With Endogenous Hypercortisolism (Cushing Syndrome) Richard J. Auchus, Aleksandra Gilis-Januszewska, Corin Badiu, Aurelian-Emil Ranetti, Alexandra Kautzky-Willer, Rosario Pivonello,

  2. Slide 2: Speaker Disclosures

    Speaker Disclosures Contracted Research Consultant • Neurocrine Biosciences/Diurnal LTD • Quest Diagnostics • Spruce Biosciences • Corcept Therapeutics • Corcept Therapeutics • Xeris Pharmaceuticals • Crinetics Pharmaceuticals • Crinetics Pharmaceuticals • Recordati Rare Diseases • Novo Nordisk • Ad

  3. Slide 3: Relacorilant: In Development for the Treatment of Endogenous Hypercortisolism (Cushing Syndrome)

    Relacorilant: In Development for the Treatment of Endogenous Hypercortisolism (Cushing Syndrome) A selective Highly glucocorticoid No clinically selective: No receptor significant impact on PR, MR, or AR ACTH levels modulator activity (SGRM) Structurally different Unique from mifepristone downstream

  4. Slide 4: The Relacorilant Long-term Extension Study

    The Relacorilant Long-term Extension Study NCT03604198 Relacorilant parent studies Phase 3 studies: Dose titration phase Maintenance phase Relacorilant QD Relacorilant QD Only for patients rolling over from a placebo design Median duration of treatment: 362 days Phase 2 Study Dose titration: 100 mg

  5. Slide 5: Longitudinal Assessments in Patients who Participated in the Phase 3 GRACE & Extension Studies

    Longitudinal Assessments in Patients who Participated in the Phase 3 GRACE & Extension Studies Phase 3 GRACE study Open-label extension study Relacorilant Patient population • 18–80 years old • Cushing syndrome Randomization Relacorilant (1:1) Relacorilant • Hypertension, hyperglycemia (impaired glu

  6. Slide 6: Patient Demographics & Baseline Characteristics

    Patient Demographics & Baseline Characteristics Extension Study: All participants Hypertension & Hypertension only Hyperglycemia only Overall Mean (SD) hyperglycemia (n=35) (n=12) (N=116) (n=69) Age, yrs 54.7 (11.6) 50.8 (15.7) 58.2 (12.4) 56.4 (12.7) Female, n (%) 28 (80.0) 12 (100.0) 50 (72.5) 90

  7. Slide 7: Longitudinal Blood Pressure Improvements in GRACE Patients who Continued in the Extension Study

    Longitudinal Blood Pressure Improvements in GRACE Patients who Continued in the Extension Study Patients with hypertension who received placebo in the GRACE RW phase Systolic Blood Pressure Diastolic Blood Pressure Mean change from BL (95% CI) Mean change from BL (95% CI) 10 10 in 24-hour DBP (mm Hg

  8. Slide 8: Longitudinal Blood Pressure Improvements in GRACE Patients who Continued in the Extension Study

    Longitudinal Blood Pressure Improvements in GRACE Patients who Continued in the Extension Study Patients with hypertension who participated in the GRACE & extension studies Systolic Blood Pressure Diastolic Blood Pressure Mean change from BL (95% CI) Mean change from BL (95% CI) 10 10 in 24-hour DBP

  9. Slide 9: Blood Pressure Continued to Improve in the Extension Study

    Blood Pressure Continued to Improve in the Extension Study Extension study patients with hypertension: All participants Average 24-h Blood Pressure (by ABPM) Mean change from baseline 0 -7.3 (95% CI) in BP (mm Hg) -5 DBP -10 SBP -15 -10.0 -20 OLE Month Month Month Month Baseline 6 12 18 24 n: 69 44

  10. Slide 10: Weight Reductions Maintained in the Extension Study

    Weight Reductions Maintained in the Extension Study Patients who participated in the GRACE & extension studies Body Weight Mean change from BL (95% CI) Relacorilant Placebo Relacorilant 0 in body weight (kg) -5 -10 Relacorilant GRACE GRACE OLE OL RW BL OL RW RW RW OLE OLE OLE W22 W4 W8 W12 M3 M12 M2

  11. Slide 11: Improvements in HbA1c Maintained in the Extension Study

    Improvements in HbA1c Maintained in the Extension Study Patients with hyperglycemia who participated in the GRACE & extension studies HbA1c Mean change from BL (95% CI) 0.5 Relacorilant Placebo Relacorilant 0.0 in HbA1c (%) -0.5 -1.0 -1.5 Relacorilant GRACE GRACE OLE -2.0 OL RW BL OL RW OLE OLE OLE

  12. Slide 12: Extension Study: Adverse Events Occurring in ≥10% of Patients

    Extension Study: Adverse Events Occurring in ≥10% of Patients Relacorilant n (%) • Relacorilant’s safety profile in the extension (N=116) Pain in extremity 27 (23.3%) study was consistent with the parent studies 25 (21.6%) (GRACE, GRADIENT, phase 2) Arthralgia Back pain 21 (18.1%) • The majority of

  13. Slide 13: Extension Study: Adverse Event Summary

    Extension Study: Adverse Event Summary Relacorilant n (%) (N=116) • Due to relacorilant’s specificity for the GR and its Patients reporting at least one TEAE unique mechanism of action, the observed 109 (94.0) efficacy was seen: (any grade) Patients reporting at least one grade 44 (37.9) • Without c

  14. Slide 14: Summary & Conclusions

    Summary & Conclusions • Relacorilant showed clinically significant and durable cardiometabolic improvements and was well-tolerated in patients with hypercortisolism treated for 6+ years • Blood pressure continued to improve during the extension study • Improvements in weight and glycemic measures we

  15. Slide 15: Thanks to all Those who Contributed to the Extension and GRACE Studies!

    Thanks to all Those who Contributed to the Extension and GRACE Studies! The investigators & their teams • Dr. Lisa Abbott (G RACE) • Prof. Dr. Martin Fassnacht • Prof. Dr. Electron Kebebew • Dr. Leszek Romanowski (G RACE) (Extension, G RA CE) (Extension) • Dr. Amer Al-Karadsheh • Dr. Pnina Rotman-Pi

Corcept Therapeutics — Technical Presentation (December 2024) on 6ix